Banking on Fostamatinib, Rigel Seeks to Raise $130M
A public offering worth $130 million will extend Rigel Pharmaceuticals Inc.'s cash runway through potential approval of its lead product, fostamatinib. The South San Francisco-based company will offer about 13.7 million shares of common stock at $9.50 per share, to close on or about Oct. 9.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST